Related Experiment Video

Updated: Mar 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity

Chao Zhao, Daulat Bikram Khadka, Won-Jea Cho1

  • 1College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea. wjcho@chonnam.ac.kr.

Current Medicinal Chemistry
|April 7, 2016
PubMed

Insights

Janus kinase 2 (JAK2) inhibitors show promise for treating myeloproliferative neoplasms and other diseases. Understanding JAK2 structural features and inhibitor binding is key to developing potent and selective drugs.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Structural Biology

Background:

  • The Janus kinase 2 (JAK2) signaling pathway is crucial for cell regulation.
  • Mutations in JAK2, like V617F, are linked to myeloproliferative neoplasms (MPNs).
  • JAK2 inhibitors are explored for MPNs, cancers, and neurodegenerative diseases.

Purpose of the Study:

  • To review the structural characteristics of JAK2-ligand complexes.
  • To summarize the structure-activity relationship (SAR) of JAK2 inhibitors.
  • To highlight features essential for potent and selective JAK2 inhibition.

Main Methods:

  • Compilation of 3D structural data for JAK2-ligand complexes.
  • Analysis of structure-activity relationships for JAK2 inhibitors.
  • Focus on structural determinants of potency and selectivity.

Main Results:

  • Detailed three-dimensional structural features of reported JAK2-ligand complexes are summarized.
  • Structure-activity relationships of various JAK2 inhibitors are discussed.
  • Key structural aspects influencing JAK2 inhibition potency and selectivity are identified.

Conclusions:

  • Knowledge of JAK2 structural characteristics and binding modes is vital for drug development.
  • Potent and selective JAK2 inhibitors are essential for therapeutic efficacy.
  • This review provides a foundation for designing next-generation JAK2-targeting agents.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.1K
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
7.0K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K